1421503-38-9

Basic information

• Product Name: 4-BROMO-5-ETHYL-2-FLUOROPHENOL
• Synonyms: 4-BROMO-5-ETHYL-2-FLUOROPHENOL;EOS-60407
• CAS NO: 1421503-38-9
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.0509232
• Mol File: 1421503-38-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-BROMO-5-ETHYL-2-FLUOROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-5-ETHYL-2-FLUOROPHENOL(1421503-38-9)
• EPA Substance Registry System: 4-BROMO-5-ETHYL-2-FLUOROPHENOL(1421503-38-9)

Safety Data

• Hazardous Substances Data: 1421503-38-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-5-ethyl-2-fluorophenol is used as an intermediate in the production of drugs and medications, playing a crucial role in the synthesis of various pharmaceutical compounds.
Used in Agrochemical Industry:
4-BROMO-5-ETHYL-2-FLUOROPHENOL is utilized in the synthesis of agrochemicals, contributing to the development of products for agricultural applications, such as pesticides and herbicides.
Used in Organic Compounds Synthesis:
4-Bromo-5-ethyl-2-fluorophenol serves as a key component in the synthesis of various organic compounds, expanding its utility in the field of organic chemistry.
Used in Antimicrobial and Antifungal Applications:
Due to its antimicrobial and antifungal properties, 4-Bromo-5-ethyl-2-fluorophenol is studied for potential use in applications that require the inhibition of microbial growth, such as in the development of disinfectants and preservatives.
Used as a Reagent in Chemical Reactions:
4-BROMO-5-ETHYL-2-FLUOROPHENOL is employed as a reagent in various chemical reactions, facilitating specific transformations and processes in the synthesis of target molecules.

Upstream product

• 891843-05-3 5-ethyl-2-fluoro-phenol 
• 112204-58-7 5-Bromo-2-fluorophenol 
• 459-47-2 1-ethyl-4-fluorobenzene 

Downstream Products

• 1421503-40-3 (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane 
• 1421503-41-4 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carbonitrile 
• 1421503-42-5 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidic acid methyl ester 
• 1421503-43-6 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine 
• 1421503-44-7 4,4-diethoxy-3-{[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidoyl]amino}piperidine-1-carboxylic acid tert-butyl ester 
• 1421502-61-5 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine 
• 1421503-39-0 (2-((4-bromo-5-ethyl-2-fluorophenoxy)methoxy)ethyl)-trimethylsilane 

Relevant articles and documents

Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism

The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) play an essential role in the receptor signaling of cytokines that have been implicated in the pathogenesis of severe asthma, and there is emerging interest in the development of small-molecule-inhaled JAK inhibitors as treatments. Here, we describe the optimization of a quinazoline series of JAK inhibitors and the results of mouse lung pharmacokinetic (PK) studies where only low concentrations of parent compound were observed. Subsequent investigations revealed that the low exposure was due to metabolism by aldehyde oxidase (AO), so we sought to identify quinazolines that were not metabolized by AO. We found that specific substituents at the quinazoline 2-position prevented AO metabolism and this was rationalized through computational docking studies in the AO binding site, but they compromised kinome selectivity. Results presented here highlight that AO metabolism is a potential issue in the lung.

JAK inhibitor compound and application thereof

The invention relates to a JAK inhibitor compound and application thereof. Specifically, the invention discloses a compound shown as a formula (G), or an isotope labeled compound, or an optical isomer, a geometrical isomer, a tautomer or an isomer mixture of the compound, or a pharmaceutically acceptable salt of the compound, or a prodrug of the compound, or a metabolite of the compound. The invention also relates to the medical application of the compound.

Design and synthesis of a Pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.